tapebrief
SOLV · Q2 2025

SOLV · Q3 2025 Earnings

Cautious

Solventum

Reported November 6, 2025

30-second summary

Solventum delivered Q3 FY2025 organic growth of 2.7% with non-GAAP EPS of $1.50, and raised FY2025 EPS guidance to $5.98–$6.08 (from the Q2 FY2025 official guide of $5.80–$5.95) while narrowing organic growth to the high end of the +2.0–3.0% range. The headline-grabber, though, is a $300M cut to the FY2025 free cash flow guide (now $150–250M, down from $450–550M) attributed entirely to Purification & Filtration divestiture costs — a one-time item that nonetheless materially reshapes the cash story management spent two quarters building. MedSurg organic decelerated to +1.1% (well below the +4% bar set last quarter), Dental organic accelerated to +6.5%, and a newly-disclosed $500M restructuring program ("Transform for the Future") promises ~$500M in gross annual savings, with a portion reinvested in growth initiatives.

Headline numbers

EPS

Q3 FY2025

$1.50

Revenue

Q3 FY2025

$2.10B

+0.7% YoY

Gross margin

Q3 FY2025

55.8%

Free cash flow

Q3 FY2025

$-0.02B

Operating margin

Q3 FY2025

20.6%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$2.10B+0.7%$2.16B-3.0%
EPS$1.50—$1.69-11.2%
Gross margin55.8%—54.4%+140bps
Operating margin20.6%—9.9%+1070bps
Free cash flow$-0.02B—$0.06B-137.3%

Guidance

Solventum raised full-year EPS guidance and reaffirmed organic growth targets at the high end, but significantly lowered free cash flow guidance due to divestiture costs.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted EPS
FY2025
$5.80 to $5.95$5.98 to $6.08+$0.18 to +$0.13 at low end; +$0.13 at high endRaised
Organic Sales Growth
FY2025
+2.0% to +3.0%high end of +2.0% to +3.0% rangeraised to high end (vs. midpoint implied prior)Raised
Free Cash Flow
FY2025
$450M to $550M$150M to $250M-$300M to -$200M (lower end); -$300M to -$400M (upper end)Lowered

Reaffirmed unchanged this quarter: Organic Sales Growth (excluding SKU exits) (high end of +2.5% to +3.5%)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
MedSurg$1.206B+2.1%
Dental Solutions$0.34B+8.4%
Health Information Systems$0.345B+5.9%
Advanced Wound Care$0.485B+3.5%
Infection Prevention and Surgical Solutions$0.722B+1.2%
Purification and Filtration$0.128B-28.7%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Organic Sales Growth (Q3)2.7%
Organic Sales Growth (9M)3.2%
Adjusted Operating Margin (Q3)20.6%
Adjusted Operating Margin (9M)20.7%
MedSurg Operating Margin (Q3)16.8%
Dental Solutions Operating Margin (Q3)25.7%
Health Information Systems Operating Margin (Q3)38.8%
FY2025 Adjusted EPS Guidance$5.98 to $6.08

Management tone

Q1 FY2025 separation-survival → Q2 FY2025 ownership-and-raise → Q3 FY2025 execution-with-divestiture-noise.

Q2 FY2025 was the moment management shifted from inheritance-framing to ownership-framing, pairing a coordinated raise on EPS, organic growth, and PNF accretion with the assertion that organic performance was "squelching doubt" on the long-range plan. Q3 FY2025 keeps the EPS confidence — a cumulative $0.13–$0.18 raise off the Q2 FY2025 official $5.80–$5.95 range — but the surrounding narrative has narrowed. Management is now leaning on two specific levers: Dental's market-share proof point and the new "Transform for the Future" program. The "five growth driver" framing remains, but with MedSurg organic decelerating to +1.1%, the burden has shifted onto Dental and HIS to carry the growth story near-term.

The introduction of a formal $500M restructuring program with ~$500M gross annual savings (a portion reinvested in growth) is the largest tonal shift from Q2 FY2025. At a pre-Q3 investor conference fireside, CFO Wade McMillan said critical stand-up investments had been "annualized" and the company was queuing up a list of efficiency levers — supplier consolidation, lean/OPEX rollout beyond manufacturing, network optimization — while emphasizing commitment to the 23–25% operating margin range. "Transform for the Future" formalizes and scales that queue. It can be read two ways: opportunistic margin expansion, or a tacit acknowledgement that organic growth alone won't close the gap to the 23–25% margin target. The press release frames it as the former.

On tariffs, the same fireside framed the approach as quarterly updates rather than intra-quarter recalibration, given the fluidity. The Q3 press release attributes adjusted operating margin compression (-220bps YoY) in part to incremental tariffs and lower gross margins but does not quantify the tariff impact in isolation; the Q3 earnings call (held the afternoon of the print) is the venue to watch for the updated tariff math.

The FCF guide cut is the most carefully-staged tonal element. Management isolated it to divestiture costs (a one-time item) rather than letting it bleed into underlying cash quality commentary. Whether that framing survives Q4 FY2025 — when the divestiture closes and FY2026 guidance is set — is the watch.

Recurring themes management leaned on this quarter:

Volume-driven turnaround replacing pricing-driven growthCommercial execution acceleration from new leadership teamFive growth driver strategy concentrating 80%+ of growth opportunityDental market recovery trajectory with product innovation unlocking market shareOperating margin expansion (23-25% target) paired with growth investmentM&A-enabled tuck-in strategy pending deleveraging completion

Risks management surfaced:

Tariff landscape remains fluid with quarterly recalibration requiredDental market recovery timing uncertain despite long-term tailwindsERP implementation execution risk during transition to new systemsInventory normalization in Q2-Q4 could reverse Q1 volume gainsClinician productivity solutions continuing double-digit declines in HIS segment

Answers to last quarter's watch list

Organic growth normalization in Q3 FY2025. Reported organic growth came in at +2.7%, well above the ~1.5% implied 2H midpoint after the Q1 FY2025 order-timing reversal. The raise was not front-loaded optics — underlying momentum sustained.
Resolved positively
MedSurg trajectory after IPSS +6.9%. MedSurg organic decelerated to +1.1% (from +4.8%) and IPSS organic specifically went to 0.0% (from +6.9%), far below the +4% bar set last quarter. The "commercial restructuring is working" thesis takes a meaningful hit on this segment specifically.
Resolved negatively
Advanced Wound Care recovery. AWC organic returned to +2.7% from +1.7%, a partial recovery that falls just short of the 3% bar on an organic basis. The Q2 FY2025 recall impact was mostly transitory but the underlying organic line isn't yet at the prior bar. Status: Mixed
Free cash flow ramp. Q3 FY2025 FCF came in at -$22M (9M FCF of -$42M), and management cut the FY2025 guide to $150–250M attributing the move entirely to divestiture costs. The original $450–550M range is gone. Underlying cash generation isn't necessarily impaired, but the headline number is.
Resolved negatively
Tariff headwind realized. The press release attributes Q3 margin compression in part to incremental tariffs without isolating the figure; per the pre-Q3 fireside, management updates tariff math on a quarterly cadence, so the earnings call is the venue for a sized impact.
Continue monitoring
FY2026 SKU rationalization framing. No FY2026 framing in the press release. At the pre-Q3 fireside, CFO McMillan indicated M&A would begin "in earnest" in 2026 on the other side of the P&F close — a useful capital-allocation signal but not an organic-growth framing. Q4 FY2025 remains the more likely venue.
Continue monitoring

What to watch into next quarter

Q4 FY2025 MedSurg / IPSS recovery. Whether IPSS organic bounces back above +4% in Q4 FY2025 or sustains the Q3 FY2025 ~0% level is the single most important segment data point for the bull thesis. Two consecutive quarters of sub-3% IPSS organic growth would force a rethink of the sterilization-assurance/NPWT/IV-site launch trajectory.

Dental sustainability above +5% organic. The +6.5% organic Q3 FY2025 print is a step-change. Watch whether Q4 FY2025 holds above +5% organic — confirming the new-product market-share narrative — or reverts toward the +2–3% range Dental ran at earlier in FY2025.

Initial FY2026 FCF framing. With FY2025 FCF now $150–250M, the FY2026 normalization path matters enormously. Management's Q4 FY2025 commentary on what cash generation looks like post-PNF-divestiture and post-separation-cost-ramp-down is the single most important capital-allocation disclosure ahead.

"Transform for the Future" execution detail. The $500M cost / ~$500M gross savings program was disclosed without phasing or net-to-P&L disclosure. Watch for the cost cadence (FY2026 weighting), the savings ramp, the reinvestment split, and where the savings hit the P&L (COGS vs SG&A) on the Q4 FY2025 call.

PNF divestiture proceeds deployment and M&A timing. The transaction closed September 1, 2025, with $3.87B in proceeds reflected in the cash flow statement and debt repayment of $2.97B already executed in the nine months. Management telegraphed at the pre-Q3 fireside that M&A would start "in earnest" in 2026 — watch for tuck-in cadence and the deleveraging glide path.

FY2026 organic growth guide vs. 100 bps SKU drag. Management telegraphed in Q2 FY2025 that SKU exits step from 50 bps to 100 bps headwind. Watch whether FY2026 guidance frames ex-SKU growth above 3% — the implicit bar for "underlying acceleration" to remain intact.

Sources

  1. Solventum Q3 FY2025 Form 8-K Exhibit 99.1 (press release) — https://www.sec.gov/Archives/edgar/data/1964738/000196473825000089/q32025-8kerexx991.htm
  2. Solventum pre-Q3 FY2025 investor conference fireside (Wade McMillan, CFO; Kareem Mansour, President, Dental Solutions) — context on tariffs, SG&A leverage, margin commitment, and M&A timing
  3. Solventum Q2 FY2025 Tapebrief (prior-quarter context for tone and watch list resolution)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.